Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GHB16L2
- Development stage
- Unknown
- Lead developer
- Baxter Healthcare Corporation
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intranasal
01
Overview
GHB16L2 is a trivalent, replication-deficient influenza vaccine candidate developed for intranasal administration. It was designed to provide immunization against seasonal influenza virus infection. The vaccine utilizes a live attenuated influenza virus platform with deletion of the non-structural protein 1 (NS1), which is intended to enhance safety and immunogenicity by preventing viral evasion of host immune responses. GHB16L2 was evaluated in a randomized, double-blind, placebo-controlled phase I/II clinical trial in healthy adults to assess its safety, tolerability, immunogenicity, and pharmacokinetics (viral shedding). The developer is Avir Green Hills Biotechnology AG[7][2].
- Brand names
- deltaFLU
- Other names
- trivalent influenza vaccine (delNS1)
02
Targets
Sialoglycan (Cell-surface sialoglycan)
Beyond the preview
Go deeper on GHB16L2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GHB16L2.